scholarly journals Comparative assessment of clinical trials, indications, pharmacokinetic parameters and side effects of approved platinum drugs

Pharmacia ◽  
2022 ◽  
Vol 69 (1) ◽  
pp. 1-7
Author(s):  
Stefka Ivanova
Keyword(s):  
Clinical Trials ◽  
Side Effects ◽  
Observational Study ◽  
Protein Binding ◽  
Anticancer Agents ◽  
Platinum Complexes ◽  
Comparative Assessment ◽  
The Other ◽  
Pharmacokinetic Parameters ◽  
Platinum Drugs

Platinum complexes are among the most commonly applied anticancer agents. The aim of current work is collection, analysing and comparative estimation of clinical trials and pharmacological indications of currently approved for application platinum detivatives: Cisplatin, Carboplatin, Oxaliplatin, Nedaplatin (Japan), Lobaplatin (China), Heptaplatin (North Korea), and Satraplatin. The other aim of the study includes the summarizing of the hystoric data for the stages of the developlement of these drugs, and the comparison of pharmacokimetic parameters, side effecs and the dose-liniting factors of the drugs. The observational study on pharmacokinetic parameters shows that protein binding decreases in order: 95% (Cisplatn); 90% (Oxaliplatin); 50% (Nedaplatin); low (Carboplatin). For every of Cisplatin, Carboplatin, Oxaliplatin have been reported more than 1000 clinical trials; for Lobaplatin, Nedaplatin, Satraplatin - about 10 trials. The differenses in dose-limiting effects are: neuro-, nephro-, ototoxicity (Cisplatin); neurotoxicity (Oxaliplatin); nephrotoxicity (Heptaplatin); myelosuppression: thrombocytopenia, neutropenia, leukopenia (Carboplatin, Nedaplatin, Satraplatin).

Development of ruthenium-based complexes as anticancer agents: toward a rational design of alternative receptor targets

2016 ◽  
Vol 36 (2) ◽  
Author(s):  
Adebayo A. Adeniyi ◽  
Peter A. Ajibade
Keyword(s):  
Clinical Trials ◽  
Side Effects ◽  
Anticancer Agents ◽  
Rational Design ◽  
Coordination Complexes ◽  
Future Prospects ◽  
Phase Ii Clinical Trials ◽  
Ru Complexes ◽  
Receptor Targets ◽  
Therapeutic Activities

AbstractIn the search for novel anticancer agents, the development of metal-based complexes that could serve as alternatives to cisplatin and its derivatives has received considerable attention in recent years. This becomes necessary because, at present, cisplatin and its derivatives are the only coordination complexes being used as anticancer agents in spite of inherent serious side effects and their limitation against metastasized platinum-resistant cancer cells. Although many metal ions have been considered as possible alternatives to cisplatin, the most promising are ruthenium (Ru) complexes and two Ru compounds, KP1019 and NAMI-A, which are currently in phase II clinical trials. The major obstacle against the rational design of these compounds is the fact that their mode of action in relation to their therapeutic activities and selectivity is not fully understood. There is an urgent need to develop novel metal-based anticancer agents, especially Ru-based compounds, with known mechanism of actions, probable targets, and pharmacodynamic activity. In this paper, we review the current efforts in developing metal-based anticancer agents based on promising Ru complexes and the development of compounds targeting receptors and then examine the future prospects.

A novel neuromotor reprogramming treatment modality for temporomandibular disorders: a pilot retrospective observational study

2021 ◽  
Author(s):  
Remillieux Franck ◽  
Typhanie Dos anjos ◽  
Chaufferin Gilles ◽  
Gerentes Philippe
Keyword(s):  
Side Effects ◽  
Observational Study ◽  
Temporomandibular Disorders ◽  
Mouth Opening ◽  
The Other ◽  
Joint Diseases ◽  
Stomatognathic System ◽  
Maximal Mouth Opening ◽  
Preliminary Study ◽  
The One

Abstract Background The purpose of this investigation was to determine if neuromotor programming using the ALLYANE® process would significantly improve mouth-opening capacity in patients suffering from temporomandibular disorders (TMD). Methods A total of 21 adult patients (20 females and 1 male; mean age = 44 years) who underwent a rehabilitation session with neuromotor reprogramming were included. Maximal mouth opening (MMO) was measured before and just after neuromotor reprogramming session. Results The results showed a statistically significant (p < 0.001) mean gain of 4.95 mm (+ 13%) after neuromotor reprogramming. Furthermore, this preliminary study showed that the gain registered in patients with a lower-than-normal mouth opening and improvement of lateral movements were greater than the one obtained with the other patients. Conclusions Although these preliminary results need confirmation, the study suggests that the use of neuromotor reprogramming in patients suffering from TMD could present new possibilities for enhanced outcomes, in particular to relax the stomatognathic system with a noninvasive, reversible therapy without known side effects, providing open new perspectives in the area of joint diseases.

scholarly journals Herbal Home Remedies for Toothache during the COVID-19 Pandemic: A Review

2021 ◽  
pp. 18-29
Author(s):  
Abhishek Kumar ◽  
Akash Kumar Giri ◽  
Bibek Kattel
Keyword(s):  
Clinical Trials ◽  
Side Effects ◽  
Dental Care ◽  
Symptomatic Treatment ◽  
Dental Pain ◽  
The Other ◽  
Commercial Products ◽  
Plant Products ◽  
Home Remedies ◽  
The World

The COVID-19 pandemic resulted in the halt of proper dental care in most of the world, except for emergency cases. And, this resulted in a lot of people seek some home remedies for relieve in dental pain. So, this article aims to list down herbal home remedies which can be very helpful in such conditions. The use of medicinal herbs for dental pain can be traced back to history in some form or the other in almost every country. These herbal home remedies have no significant side effects as compared to other chemical-based alternatives, are also easy to obtain and cheaper as well. Clove, Olive, Miswak, Babool and other herbs listed in the article have significant dental properties which have been validated scientifically through various researches. These plant products can be hence used in commercial products as well but only after proper clinical trials. Further research should be encouraged in this field as herbal alternatives can be very beneficial with no such side effects. However, these home remedies are only useful for symptomatic treatment and undergoing proper dental care is advised.

The use of benzodiazepines for tinnitus: systematic review

2015 ◽  
Vol 129 (S3) ◽  
pp. S14-S22 ◽  
Author(s):  
N E Jufas ◽  
R Wood
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Side Effects ◽  
Half Life ◽  
Evidence Base ◽  
Risk Of Bias ◽  
The Other ◽  
Subjective Tinnitus ◽  
Benzodiazepine Use ◽  
Robust Evidence

AbstractObjectives:To investigate the effectiveness of benzodiazepine use for subjective tinnitus and to consider this in the context of the concomitant side effects.Methods:A systematic search of several databases using the terms ‘tinnitus’ and ‘benzodiazepines’ was conducted to find clinical trials of benzodiazepines and comparators in tinnitus patients. These studies were then assessed for risk of bias.Results:Six clinical trials were included. Clonazepam was found to be effective in three studies, but these studies had limitations regarding adequate blinding. The effectiveness of alprazolam was equivocal. Diazepam was not effective in two studies and oxazepam was effective in one study.Conclusion:Benzodiazepine use for subjective tinnitus does not have a robust evidence base. Clonazepam has the most evidence to support its use and is relatively less likely to lead to abuse because of its longer half-life, but caution is still needed given the other serious side effects.

scholarly journals Sirolimus in Infants with Multiple Cardiac Rhabdomyomas Associated with Tuberous Sclerosis Complex

2018 ◽  
Vol 11 (2) ◽  
pp. 425-430 ◽  
Author(s):  
Maurizio Lucchesi ◽  
Enrico Chiappa ◽  
Flavio Giordano ◽  
Francesco Mari ◽  
Lorenzo Genitori ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Case Report ◽  
Side Effects ◽  
Tuberous Sclerosis ◽  
Mtor Inhibitor ◽  
Complete Response ◽  
The Other ◽  
Cardiac Response ◽  
Neonatal Deaths ◽  
Tumor Debulking

Introduction: Cardiac rhabdomyomas represent a frequent manifestation of tuberous sclerosis. Tumor growth, mainly prenatally, can result in intrauterine fetal or neonatal deaths in almost 10% of patients. Case Report: We treated 3 consecutive infants aged less than 12 months with sirolimus, an oral mTOR inhibitor. All patients achieved significant reductions in cardiac rhabdomyomas. A complete response was documented in 2 patients, while a partial response with tumor debulking greater than 50% was seen in the other one. The median time to best cardiac response was 1.9 months in all patients, and 3.3 months in those with complete response. The side effects profile was acceptable. Conclusion: Sirolimus may have a significant role in promoting natural regression of cardiac rhabdomyomas. Prospective clinical trials are needed.

scholarly journals Monofunctional Platinum(II) Anticancer Agents

2021 ◽  
Vol 14 (2) ◽  
pp. 133
Author(s):  
Suxing Jin ◽  
Yan Guo ◽  
Zijian Guo ◽  
Xiaoyong Wang
Keyword(s):  
Drug Resistance ◽  
Side Effects ◽  
Cancer Cells ◽  
General Formula ◽  
Anticancer Drugs ◽  
Anticancer Agents ◽  
Platinum Drugs ◽  
Cellular Distribution ◽  
Platinum Anticancer Drugs ◽  
Tumor Selectivity

Platinum-based anticancer drugs represented by cisplatin play important roles in the treatment of various solid tumors. However, their applications are largely compromised by drug resistance and side effects. Much effort has been made to circumvent the drug resistance and general toxicity of these drugs. Among multifarious designs, monofunctional platinum(II) complexes with a general formula of [Pt(3A)Cl]+ (A: Ammonia or amine) stand out as a class of “non-traditional” anticancer agents hopeful to overcome the defects of current platinum drugs. This review aims to summarize the development of monofunctional platinum(II) complexes in recent years. They are classified into four categories: fluorescent complexes, photoactive complexes, targeted complexes, and miscellaneous complexes. The intention behind the designs is either to visualize the cellular distribution, or to reduce the side effects, or to improve the tumor selectivity, or inhibit the cancer cells through non-DNA targets. The information provided by this review may inspire researchers to conceive more innovative complexes with potent efficacy to shake off the drawbacks of platinum anticancer drugs.

Recent Advances in the Rational Drug Design Based on Multi-target Ligands

2020 ◽  
Vol 27 (28) ◽  
pp. 4720-4740 ◽  
Author(s):  
Ting Yang ◽  
Xin Sui ◽  
Bing Yu ◽  
Youqing Shen ◽  
Hailin Cong
Keyword(s):  
Drug Resistance ◽  
Clinical Practice ◽  
Side Effects ◽  
Drug Design ◽  
Rational Drug Design ◽  
Health Conditions ◽  
Pharmacokinetic Parameters ◽  
Single Target ◽  
Rational Drug ◽  
Huge Challenge

Multi-target drugs have gained considerable attention in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance. Single-target drugs, although highly selective, may not necessarily have better efficacy or fewer side effects. Therefore, more attention is being paid to developing drugs that work on multiple targets at the same time, but developing such drugs is a huge challenge for medicinal chemists. Each target must have sufficient activity and have sufficiently characterized pharmacokinetic parameters. Multi-target drugs, which have long been known and effectively used in clinical practice, are briefly discussed in the present article. In addition, in this review, we will discuss the possible applications of multi-target ligands to guide the repositioning of prospective drugs.

A Brief Review on the Development of Novel Potentially Active Azetidin-2-ones Against Cancer

2020 ◽  
Vol 24 (5) ◽  
pp. 473-486 ◽  
Author(s):  
Ligia S. da Silveira Pinto ◽  
Thatyana R. Alves Vasconcelos ◽  
Claudia Regina B. Gomes ◽  
Marcus Vinícius N. de Souza
Keyword(s):  
Side Effects ◽  
Anticancer Agents ◽  
Heterocyclic Compounds ◽  
Biological Activities ◽  
Present Review ◽  
Pharmacological Properties ◽  
Important Group ◽  
Wide Range ◽  
Anti Inflammatory

Azetidin-2-ones (&#946;-lactams) and its derivatives are an important group of heterocyclic compounds that exhibit a wide range of pharmacological properties such as antibacterial, anticancer, anti-diabetic, anti-inflammatory and anticonvulsant. Efforts have been made over the years to develop novel congeners with superior biological activities and minimal potential for undesirable side effects. The present review aimed to highlight some recent discoveries (2013-2019) on the development of novel azetidin-2-one-based compounds as potential anticancer agents.

Current Status and Future Perspective for Research on Medicinal Plants with Anticancerous Activity and Minimum Cytotoxic Value

2019 ◽  
Vol 20 (12) ◽  
pp. 1227-1243
Author(s):  
Hina Qamar ◽  
Sumbul Rehman ◽  
D.K. Chauhan
Keyword(s):  
Side Effects ◽  
Medicinal Plants ◽  
Anticancer Agents ◽  
Drug Targets ◽  
Psidium Guajava ◽  
Current Status ◽  
Future Perspective ◽  
Wide Range

Cancer is the second leading cause of morbidity and mortality worldwide. Although chemotherapy and radiotherapy enhance the survival rate of cancerous patients but they have several acute toxic effects. Therefore, there is a need to search for new anticancer agents having better efficacy and lesser side effects. In this regard, herbal treatment is found to be a safe method for treating and preventing cancer. Here, an attempt has been made to screen some less explored medicinal plants like Ammania baccifera, Asclepias curassavica, Azadarichta indica, Butea monosperma, Croton tiglium, Hedera nepalensis, Jatropha curcas, Momordica charantia, Moringa oleifera, Psidium guajava, etc. having potent anticancer activity with minimum cytotoxic value (IC50 >3μM) and lesser or negligible toxicity. They are rich in active phytochemicals with a wide range of drug targets. In this study, these medicinal plants were evaluated for dose-dependent cytotoxicological studies via in vitro MTT assay and in vivo tumor models along with some more plants which are reported to have IC50 value in the range of 0.019-0.528 mg/ml. The findings indicate that these plants inhibit tumor growth by their antiproliferative, pro-apoptotic, anti-metastatic and anti-angiogenic molecular targets. They are widely used because of their easy availability, affordable price and having no or sometimes minimal side effects. This review provides a baseline for the discovery of anticancer drugs from medicinal plants having minimum cytotoxic value with minimal side effects and establishment of their analogues for the welfare of mankind.

Nitrogen Mustards as Alkylating Agents: A Review on Chemistry, Mechanism of Action and Current USFDA Status of Drugs

2019 ◽  
Vol 19 (9) ◽  
pp. 1080-1102 ◽  
Author(s):  
Ghansham S. More ◽  
Asha B. Thomas ◽  
Sohan S. Chitlange ◽  
Rabindra K. Nanda ◽  
Rahul L. Gajbhiye
Keyword(s):  
Side Effects ◽  
Mechanism Of Action ◽  
Anticancer Agents ◽  
Nitrogen Mustard ◽  
Alkylating Agents ◽  
Cross Linking ◽  
Nitrogen Mustards ◽  
Information Leaflets ◽  
Anti Cancer ◽  
Approved Drugs

Background & Objective: :Nitrogen mustard derivatives form one of the major classes of anti-cancer agents in USFDA approved drugs list. These are polyfunctional alkylating agents which are distinguished by a unique mechanism of adduct formation with DNA involving cross-linking between guanine N-7 of one strand of DNA with the other. The generated cross-linking is irreversible and leads to cell apoptosis. Hence it is of great interest to explore this class of anticancer alkylating agents.Methods::An exhaustive list of reviews, research articles, patents, books, patient information leaflets, and orange book is presented and the contents related to nitrogen mustard anti-cancer agents have been reviewed. Attempts are made to present synthesis schemes in a simplified manner. The mechanism of action of the drugs and their side effects are also systematically elaborated.Results::This review provides a platform for understanding all aspects of such drugs right from synthesis to their mechanism of action and side effects, and lists USFDA approved ANDA players among alkylating anticancer agents in the current market.Conclusion: :Perusing this article, generic scientists will be able to access literature information in this domain easily to gain insight into the nitrogen mustard alkylating agents for further ANDA development. It will help the scientific and research community to continue their pursuit for the design of newer and novel heterocyclic alkylating agents of this class in the coming future.

Sign in / Sign up

Export Citation Format

Share Document